Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma

Summary

It was previously shown that \[18F\]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients. However, its impact on patient outcome defined as survival, costs, and/or quality of life has not been demonstrated. Regulatory agencies require randomized trials to determine the impact of PET on patient management and outcome. In this study we hypothesize that the addition of FDOPA PET will improve patient outcome by more accurately identifying presence or absence of tumor recurrence than conventional imaging.

Timeline

Start

2014-05

Primary completion

2016-03

Completion

2016-03

Outcome

Outcome not reported

Stopped: “PI left HMRI”

Drugs

Indications